

Medibio Adds Health IT & Medical Device Expertise With The Appointment Of Dr. Matt Mesnik as Non-Executive Director

Melbourne, Australia and Minneapolis, MN – 2 March 2022: Medibio Limited (“MEB” or “Medibio”) (ASX: MEB) (OTCPINK: MDBIF) is pleased to welcome Dr. Matt Mesnik to its Board of Directors as Non-Executive Director with immediate effect.

Dr. Mesnik is a physician, business executive, health IT and medical device entrepreneur. In addition to being Medibio’s first Chief Medical Officer (CMO) (some years ago), Dr. Mesnik has served in the following roles, over the course of his 30-plus-year career: Emergency Physician and Emergency Department and Urgent Care Medical Director; CMO of CVS-MinuteClinic (which during his tenure grew from 80 clinics in 9 states to more than 650 in 27 states, with more than 12 million annual patient visits); CMO of Aprima Medical Software, an electronic health records company; Co-founder and CMO of Sanso, a medical device company to improve the care of COPD patients; and CMO of Ativa Medical, Vigilant Diagnostics and Quick Check Health. Currently, Dr. Mesnik serves as CMO of Spok, a clinical communication and collaboration company serving more than 2,200 hospitals in the US, Australia and Canada. In addition, Dr. Mesnik has served as director and a consultant to several health, IT, and medical device companies and is currently a clinical and technical advisor to iGan Partners, Canada’s largest health tech VC.

Dr. Mesnik’s unique diversity of expertise across multiple disciplines and demonstrated ability to execute strategic and tactical plans has earned him a reputation as an accomplished healthcare executive who develops quality solutions and delivers strong financial results.

“I am thrilled to have Matt join Medibio’s Board of Directors,” said Medibio Co-Founder and Managing Director Claude Solitario. “I have enjoyed a long and productive business relationship with Matt since before his appointment as Medibio’s first CMO. His breadth and depth of knowledge and experience in the US health IT and medical device industry is truly unique, as are his networking skills. I believe his intimate knowledge of Medibio will enable Matt to provide valuable and expeditious advice to the Company as we approach the final stages of the FDA validation trial for MEB-001 and the go-market strategy for our non-clinical products, and I look forward to his contribution to the Board.”

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

For Further information:

Claude Solitario
Managing Director & CEO
T: +61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.